We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.

Grünenthal. Change is possible.

locations
30

We are present in 30 countries with affiliates in Europe, Latin America and the US.

market presence
100

Our products are sold in more than 100 countries.

employees
5,200

5,200 employees work for our group worldwide.

Success can only be achieved through close collaborations with those who share the same vision.


Please read more about our projects supported by resources of the European Regional Development Fund

... Read More

What we do

As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.

... Learn more about Grünenthal

Pioneering thinkers

Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
... Find out more

Careers

Ready to create a brighter future for our patients?
With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.

... Work with Grünenthal

Featured news & articles

Mohamed Adib & Monique Mendel Ott
Doctor & Patient
Employees
Team at the Grünenthal Booth - 17th World Congress on Pain (IASP 2018)

Graduate program

Developing a diverse skillset

Monique Mendel Ott recently accepted a job as a regulatory professional at Grünenthal – after completing our two-year graduate trainee program. Together with her mentor, Mohamed Adib, she shares insights into her development journey and the new career path she’s now exploring

Author: Janine Bleilevens

US Patient Day

Listening to patients’ voices

Patients know what they need: That’s why listening to their insights is a key element of Grünenthal’s approach to research and development. We’re committed to constant dialogue with pain patients – and this spirit of openness was at the heart of our recent US Patient Day.

Author: Lars Joensson

Graduate program

A golden opportunity

We offer graduates a unique chance to step into our uniquely supportive workplace culture, becoming part of our international and diverse team and experiencing the rewarding purpose of our work: to significantly improve patients’ lives through innovation.

Author: Janine Bleilevens

IASP World Congress

Joining forces to change lives

Many hands make light work – and many scientists working together have a better chance of creating life-changing new treatments for patients in pain. That’s why experts from Grünenthal recently attended the IASP World Congress to present projects and initiatives that are opening up collaboration and exploring innovative ways of improving patients’ lives.

Author: John Bothmer

11/14/2018

Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.

11/5/2018

Aachen, Germany, 5 November 2018 – Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.

10/30/2018

Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers.

10/10/2018

Aachen, Germany, 9 October 2018 – Kerstin Nacken took over the newly created position "Head Editorial Management and Media Relations" at Grünenthal on 1 September 2018. In this function she is responsible for all media related activities of the research-based pharmaceutical company and heads the editorial team for internal and external corporate channels.

8/28/2018

Aachen, Germany, 28 August 2018 – Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.

6/21/2018

Aachen, Dortmund and Göttingen, Germany, June 21, 2018 – Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder. The collaboration combines the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal’s competency in drug discovery and development as well as pain management. The project’s scientific foundation was laid at MPI-EM by Michael Sereda, Klaus-Armin Nave and Moritz Rossner.